Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Gastro-enteropancreatic neuroendocrine tumor × Nivolumab × 30 days × Clear all

Sponsor

Conditions

Melanoma 24 Carcinoma, Renal Cell 18 Carcinoma, Non-Small-Cell Lung 18 Lung Neoplasms 11 Neoplasm Metastasis 10 Stomach Neoplasms 9 Squamous Cell Carcinoma of Head and Neck 7 Carcinoma, Hepatocellular 7 Adenocarcinoma Of Esophagus 7 Skin Neoplasms 6 Neoplasms 6 Carcinoma, Transitional Cell 6 Urinary Bladder Neoplasms 5 Small Cell Lung Carcinoma 4 Ovarian Neoplasms 4 Glioblastoma 4 Esophageal Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Merkel Cell 4 Brain Neoplasms 4 Urethral Neoplasms 3 Triple Negative Breast Neoplasms 3 Prostatic Neoplasms 3 Oropharyngeal Neoplasms 3 Nasopharyngeal Carcinoma 3 Multiple Myeloma 3 Mouth Neoplasms 3 Lymphoma, Non-Hodgkin 3 Liver Neoplasms 3 Hodgkin Disease 3

Interventions

pasireotide 1 E-7386 1 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡